A greater portion, 30-35% of ET and MF patients, harbor mutations in calreticulin (CALR), a multifunctional protein typically resident in the endoplasmic reticulum, but occasionally exposed at the cell surface (29, 30, 34). The gene discussed is CALR; the disease is essential thrombocythemia.